Last reviewed · How we verify
Low Dose Corticosteroids
Low-dose corticosteroids suppress immune and inflammatory responses by binding glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Low-dose corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel disease.
At a glance
| Generic name | Low Dose Corticosteroids |
|---|---|
| Also known as | prednisone, methylprednisolone, Solumedrol |
| Sponsor | Rutgers, The State University of New Jersey |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Inflammatory diseases |
| Phase | FDA-approved |
Mechanism of action
Corticosteroids work by translocating to the nucleus and modulating gene expression of inflammatory mediators, reducing T-cell activation, and decreasing production of cytokines like TNF-α and IL-6. At low doses, these effects provide anti-inflammatory benefits while minimizing systemic adverse effects associated with higher-dose therapy.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Inflammatory bowel disease
- Asthma
- Chronic obstructive pulmonary disease
Common side effects
- Osteoporosis
- Infection (increased susceptibility)
- Hyperglycemia
- Hypertension
- Weight gain
- Insomnia
- Mood changes
Key clinical trials
- Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis (PHASE2)
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) (PHASE2)
- Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS (PHASE1, PHASE2)
- Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency (PHASE4)
- Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial (PHASE2)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- Twice Weekly Steroids and Exercise as Therapy for DMD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Dose Corticosteroids CI brief — competitive landscape report
- Low Dose Corticosteroids updates RSS · CI watch RSS
- Rutgers, The State University of New Jersey portfolio CI